Pfizer/AstraZeneca: Battleground Shifts To U.K. Parliament
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer CEO Read tried to assure U.K. legislators that an acquisition of the country’s second-largest drug company would not stunt pharma R&D in Britain at a May 13hearing. AstraZeneca CEO Soriot countered that the company’s pipeline will progress quicker if the company remains independent, resulting in future benefits to the U.K.
You may also be interested in...
GSK Applauds U.K.'s Tax Changes, Announces New Jobs And Manufacturing Facilities
GlaxoSmithKline is to invest £500 million in new U.K. manufacturing facilities in Ulverston, Montrose and Irvine, creating 1,000 jobs in the process.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.